Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02072681
Other study ID # 20120079
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 2015
Est. completion date June 30, 2021

Study information

Verified date July 2021
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The objective of this study is to determine the 90-day outcomes of mild and rapidly improving ischemic stroke.


Recruitment information / eligibility

Status Completed
Enrollment 2175
Est. completion date June 30, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Mild or spontaneously rapidly improving ischemic stroke confirmed by neuroimaging - Arrival to hospital within 4.5 hours of symptom onset - Willing to provide consent - Available for a telephone interview at 30 and 90 days Exclusion Criteria: - Onset >4.5 hours - Unable to provide informed consent (patient or legally appointed representative - Premorbid modified Rankin Scale >1 - Unavailable by telephone for follow-up

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Saint Peter's Hospital Albany New York
United States UPMC Altoona Altoona Pennsylvania
United States Alexian Brothers Arlington Heights Illinois
United States King's Daughters Medical Center Ashland Kentucky
United States Seton Medical Center Austin Texas
United States Seton Medical Center-Brackenridge Austin Texas
United States St. David's Medical Center/Neuro Texas Institute Austin Texas
United States Eastern Maine Medical Center Bangor Maine
United States Overlake Hospital Medical Center Bellevue Washington
United States Boston Medical Center Boston Massachusetts
United States Ocean Medical Center Brick New Jersey
United States Albert Einstein College of Medicine-Montefiore Medical Center Bronx New York
United States New York Methodist Hospital Brooklyn New York
United States SUNY Downstate Medical Center Brooklyn New York
United States Mercy Hospital of Buffalo Buffalo New York
United States University of Vermont Burlington Vermont
United States Chandler Regional Medical Center Chandler Arizona
United States Carolinas HealthCare System Charlotte North Carolina
United States University of Cincinnati Medical Center Cincinnati Ohio
United States Kaiser Permanente Northwest Sunnyside Medical Center Clackamas Oregon
United States MetroHealth Medical Center Cleveland Ohio
United States Memorial Hospital Central Colorado Springs Colorado
United States Ohio State University Wexner Medical Center Columbus Ohio
United States Ascencion-St. John Providence Detroit Michigan
United States Henry Ford Health System Detroit Michigan
United States Saint Vincent Hospital Erie Pennsylvania
United States UPMC Hamot Erie Pennsylvania
United States Lutheran Hospital Fort Wayne Indiana
United States Parkview Research Center Fort Wayne Indiana
United States JPS Health Network Fort Worth Texas
United States Shands Hospital- University of Florida Gainesville Florida
United States Methodist Hospitals Gary Indiana
United States Spectrum Health Grand Rapids Michigan
United States Greenville Memorial Hospital Greenville South Carolina
United States Pennsylvania State University / The Milton S. Hershey Medical Center Hershey Pennsylvania
United States The Queen's Medical Center Honolulu Hawaii
United States Houston Methodist Hospital Houston Texas
United States St. Vincent Hospital Indianapolis Indianapolis Indiana
United States Mississippi Baptist Medical Center Jackson Mississippi
United States University of Mississippi Medical Center Jackson Mississippi
United States Conemaugh Memorial Medical Center Johnstown Pennsylvania
United States Ascension-Borgess Kalamazoo Michigan
United States St. Luke's Neuroscience Institute Kansas City Missouri
United States Osceola Regional Medical Center Kissimmee Florida
United States Baptist Health Lexington Lexington Kentucky
United States Long Beach Memorial Medical Center Long Beach California
United States Good Samaritan Hospital Los Angeles California
United States Kaiser Permanente South California Los Angeles California
United States Norton HealthCare Louisville Kentucky
United States University of Louisville Louisville Kentucky
United States Medical Center, Navicent Health Macon Georgia
United States WellStar Health System-Kennestone Hospital Marietta Georgia
United States Jackson Memorial Hospital Miami Florida
United States Aurora BayCare Medical Center Milwaukee Wisconsin
United States Aurora Medical Center Grafton Milwaukee Wisconsin
United States Aurora St. Luke's Medical Center Milwaukee Wisconsin
United States Providence Holy Cross Medical Center Mission Hills California
United States Riverside University Health System Medical Center Moreno Valley California
United States Carolina Healthcare Blue Ridge Morganton North Carolina
United States West Virginia University Morgantown West Virginia
United States Intermountain Medical Center Neuroscience Institute Murray Utah
United States Hackensack Meridian Health/Jersey Shore University Medical Center Neptune New Jersey
United States The Hospital of Central Connecticut New Britain Connecticut
United States Ochsner Medical Center New Orleans Louisiana
United States Bon Secours Hampton Roads Norfolk Virginia
United States INTEGRIS Baptist Medical Center Oklahoma City Oklahoma
United States Mercy Hospital Oklahoma City Oklahoma
United States Florida Hospital Orlando Florida
United States Southern California Permanente Medical Group / Downey Pasadena California
United States St. Joseph's Regional Medical Center Paterson New Jersey
United States Sacred Heart Hospital Pensacola Florida
United States Berkshire Medical Center Pittsfield Massachusetts
United States Pomona Valley Hospital Medical Center Pomona California
United States Legacy Emanuel Medical Center Portland Oregon
United States Providence St. Vincent Portland Oregon
United States Rhode Island Hospital Providence Rhode Island
United States The Valley Hospital Ridgewood New Jersey
United States Rochester General Hospital Rochester New York
United States Univ of Rochester - Strong Memorial Hospital Rochester New York
United States Kaiser Permanente Northern California (Sacramento) Sacramento California
United States Mercy Hospital St. Louis Saint Louis Missouri
United States SSM Health Care St. Louis Saint Louis Missouri
United States St. Anthony's Medical Center Saint Louis Missouri
United States Orange County Global Medical Center Santa Ana California
United States HonorHealth Scottsdale Arizona
United States Cox Medical Centers Springfield Missouri
United States Memorial Medical Center Springfield Illinois
United States Crouse Hospital Syracuse New York
United States Morton Plant Mease Healthcare Tampa Florida
United States Scott & White Memorial Hospital Temple Texas
United States Saint Francis Hospital Tulsa Oklahoma
United States Faxton St. Luke's Healthcare Utica New York
United States Clear Lake Regional Medical Center Webster Texas
United States Wesley Medical Center Wichita Kansas
United States Central DuPage Hospital Association Winfield Illinois
United States Novant Forsyth Medical Center Winston-Salem North Carolina
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of Miami American Heart Association, Genentech, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (4)

Romano JG, Gardener H, Campo-Bustillo I, Khan Y, Riley N, Tai S, Sacco RL, Khatri P, Smith EE, Schwamm LH. The Mild and Rapidly Improving Stroke Study (MaRISS): Rationale and design. Int J Stroke. 2019 Dec;14(9):983-986. doi: 10.1177/1747493019873595. Epub 2019 Sep 7. — View Citation

Romano JG, Gardener H, Campo-Bustillo I, Khan Y, Tai S, Riley N, Smith EE, Sacco RL, Khatri P, Alger HM, Mac Grory B, Gulati D, Sangha NS, Craig JM, Olds KE, Benesch CG, Kelly AG, Brehaut SS, Kansara AC, Schwamm LH; MaRISS Investigators*. Predictors of Ou — View Citation

Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, Cook A, Campo-Bustillo I, Khatri P, Bhatt DL, Fonarow GC, Sacco RL, Schwamm LH. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry. JAMA Neurol. 2015 Apr;72(4):423-31. doi: 10.1001/jamaneurol.2014.4354. — View Citation

Romano JG, Smith EE, Liang L, Gardener H, Campo-Bustillo I, Khatri P, Bhatt DL, Fonarow GC, Sacco RL, Schwamm LH. Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics. Stroke. 2016 May;47(5):1278-85. doi: 10.1161/STROKEAHA.115.011528. Epub 2016 Mar 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients not independent at 90 days The primary outcome measure is proportion of patients with a modified Rankin Scale of 2-6 at 90 days 90 days
Secondary Proportion of patients with dependence or disability in activities of daily living at 90 days Proportion of patients not independent in activities of daily living defined as a Barthel Index score <95 90 days
Secondary Symptomatic intracranial hemorrhage due to Alteplase Amongst those that receive intravenous Alteplase, a secondary safety measure is the proportion of patients that develop neurologic worsening development of symptomatic intracerebral hemorrhage, defined as neurological deterioration that, in the judgment of the investigator, is related to intracranial hemorrhage confirmed by CT or MRI, within 36 hours of administration of Alteplase. 36 hours
Secondary Proportion of patients not independent at 30 days Proportion of patients with modified Rankin Scale 2-6 at 30 days. 30 days
Secondary Quality of life by the EuroQOL EQ-5D EuroQOL will be treated as a continuous measure 90 days
Secondary Stroke disability by the Stroke-Impact Scale-16 SIS-16 will be treated as a continuous measure 90 days
Secondary Independence with Activities of Daily Living by the Barthel Index BI will be treated as a continuous measure; pre specified analysis include proportion of patients with Barthel Index <95 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A